106 related articles for article (PubMed ID: 6416744)
21. [Progress in the contraceptive use of the LH-RH agonist buserelin: intermittent medication with gestagen-induced withdrawal bleeding].
Hardt W; Schmidt-Gollwitzer K; Nevinny-Stickel J; Schmidt-Gollwitzer M
Geburtshilfe Frauenheilkd; 1982 Dec; 42(12):874-7. PubMed ID: 6819180
[TBL] [Abstract][Full Text] [Related]
22. Ovulation inhibition by daily i.m. administration of a highly active LH-RH analog (d-ser(TBU)6-LH-RH-(1-9)-nonapeptide-ethylamide).
Baumann R; Kuhl H; Taubert HD; Sandow J
Contraception; 1980 Feb; 21(2):191-7. PubMed ID: 6768492
[TBL] [Abstract][Full Text] [Related]
23. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
Kekkonen R; Alfthan H; Haukkamaa M; Heikinheimo O; Luukkainen T; Lähteenmäki P
Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
[TBL] [Abstract][Full Text] [Related]
24. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.
Kekkonen R; Lähteenmäki P; Luukkainen T; Tuominen J
Fertil Steril; 1993 Oct; 60(4):610-5. PubMed ID: 8405512
[TBL] [Abstract][Full Text] [Related]
25. Longitudinal ultrasonographic study of the ovarian suppressive activity of a low-dose triphasic oral contraceptive during correct and incorrect pill intake.
Hamilton CJ; Hoogland HJ
Am J Obstet Gynecol; 1989 Nov; 161(5):1159-62. PubMed ID: 2686444
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of ovulation in women by intranasal treatment with a luteinizing hormone-releasing hormone agonist.
Bergquist C; Nillius SJ; Wide L
Contraception; 1979 May; 19(5):497-506. PubMed ID: 380892
[TBL] [Abstract][Full Text] [Related]
27. Effects of a single contraceptive Silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years.
Barbosa I; Coutinho E; Hirsch C; Ladipo O; Olsson SE; Ulmsten U
Fertil Steril; 1996 Apr; 65(4):724-9. PubMed ID: 8654629
[TBL] [Abstract][Full Text] [Related]
28. Long-term intranasal luteinizing hormone-releasing hormone agonist treatment for contraception in women.
Bergquist C; Nillius SJ; Wide L
Fertil Steril; 1982 Aug; 38(2):190-3. PubMed ID: 6809500
[TBL] [Abstract][Full Text] [Related]
29. Peptide contraception in women. Inhibition of ovulation by chronic intranasal LRH agonist therapy.
Bergquist C; Nillius SJ; Wide L
Ups J Med Sci; 1984; 89(2):99-106. PubMed ID: 6431676
[TBL] [Abstract][Full Text] [Related]
30. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
Carlström K; Lunell NO; Zador G
Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
[TBL] [Abstract][Full Text] [Related]
31. Effects of different doses of norethisterone on ovarian function, serum sex hormone binding globulin and high density lipoprotein-cholesterol.
Song S; Chen JK; Lu CH; Yang PJ; Yang QY; Fan BC; He ML; Gui YL; Li LM; Fotherby K
Contraception; 1993 Jun; 47(6):527-37. PubMed ID: 8334889
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of ovulation by intranasal nafarelin, a new superactive agonist of GnRH.
Gudmundsson JA; Nillius SJ; Bergquist C
Contraception; 1984 Aug; 30(2):107-14. PubMed ID: 6238805
[TBL] [Abstract][Full Text] [Related]
33. Early follicular phase luteinizing hormone-releasing hormone agonist administration - effects on follicular maturation and corpus luteum function in women.
Skarin G; Nillius SJ; Wide L
Contraception; 1982 Jan; 25(1):31-9. PubMed ID: 6800690
[TBL] [Abstract][Full Text] [Related]
34. Pituitary and ovarian function in women receiving hormonal contraception.
Cohen BL; Katz M
Contraception; 1979 Nov; 20(5):475-87. PubMed ID: 393456
[TBL] [Abstract][Full Text] [Related]
35. Endometrial histology during intermittent intranasal luteinizing hormone-releasing hormone (LH-RH) agonist sequentially combined with an oral progestogen as an antiovulatory contraceptive approach.
Lemay A; Jean C; Faure N
Fertil Steril; 1987 Nov; 48(5):775-82. PubMed ID: 2959569
[TBL] [Abstract][Full Text] [Related]
36. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel.
Davies GC; Feng LX; Newton JR; Van Beek A; Coelingh-Bennink HJ
Contraception; 1993 Mar; 47(3):251-61. PubMed ID: 8462316
[TBL] [Abstract][Full Text] [Related]
37. Intranasal gonadotropin-releasing hormone agonist as a contraceptive agent.
Bergquist C; Nillius SJ; Wide L
Lancet; 1979 Aug; 2(8136):215-7. PubMed ID: 89330
[TBL] [Abstract][Full Text] [Related]
38. Dynamic testing of hypothalamic-pituitary function in abnormalities of ovulation.
Jones GE; Wentz AC; Rosenwaks Z; Shoemaker J
Am J Obstet Gynecol; 1977 Dec; 129(7):760-76. PubMed ID: 343592
[TBL] [Abstract][Full Text] [Related]
39. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
[TBL] [Abstract][Full Text] [Related]
40. Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17 beta-estradiol.
Wenzl R; Bennink HC; van Beek A; Spona J; Huber J
Fertil Steril; 1993 Oct; 60(4):616-9. PubMed ID: 8405513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
